H.R. 9598

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9598 Referred in Senate (RFS)]

<DOC>
118th CONGRESS
2d Session
H. R. 9598

_______________________________________________________________________

IN THE SENATE OF THE UNITED STATES

December 9, 2024

Received; read twice and referred to the Committee on the Judiciary

_______________________________________________________________________

AN ACT

To amend the Office of National Drug Control Policy Reauthorization Act 
to reauthorize such Office, and for other purposes.

Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ``Office of National Drug Control 
Policy Reauthorization Act of 2024''.

SEC. 2. OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION.

(a) Amendments to the Office of National Drug Control Policy 
Reauthorization Act of 1998.--The Office of National Drug Control 
Policy Reauthorization Act of 1998 (21 U.S.C. 1701 et seq.) is 
amended--
(1) in section 702 (21 U.S.C. 1701)--
(A) in paragraph (2)(A)(ii), by striking 
``Government Reform'' and inserting ``Accountability'';
(B) in paragraph (3)--
(i) in subparagraph (L), by striking ``; 
and'' and inserting a semicolon;
(ii) in subparagraph (M), by striking the 
period at the end and inserting ``; and''; and
(iii) by adding at the end the following:
``(N) tertiary prevention support or services, 
including opioid antagonists or overdose reversal 
agents such as naloxone, and other harm reduction 
activities such as overdose and drug detection 
testing.'';
(C) by amending paragraph (7) to read as follows:;
``(7) Emerging drug threat.--The term `emerging drug 
threat' means the occurrence of a new and growing trend in the 
illicit use or misuse of a drug, class of drugs, or non-
controlled substance, or a new or evolving method of drug 
consumption or trafficking, including rapid expansion in the 
supply of or demand for such a drug or substance.''.
(D) in paragraph (9), by striking ``drug laws'' and 
inserting the following: ``drug, trade, and illicit 
drug trafficking laws'';
(E) in paragraph (10), by inserting after ``demand 
reduction,'' the following: ``illicit drug 
trafficking,'';
(F) by redesignating paragraphs (15), (16), and 
(17) as paragraphs (17), (18), and (19), respectively;
(G) by inserting after paragraph (14) the following 
new paragraph:
``(15) Precursor chemical.--
``(A) In general.--The term `precursor chemical' 
includes a listed chemical and an unregulated 
precursor.
``(B) Listed chemical.--The term `listed chemical' 
has the meaning given that term in section 102 of the 
Controlled Substances Act (21 U.S.C. 802).
``(C) Unregulated precursor.--The term `unregulated 
precursor'--
``(i) means any chemical used in the 
production of illicit drugs that has not been 
identified as a listed chemical under the 
Controlled Substances Act; and
``(ii) does not include a solvent or 
reagent.
``(16) State.--The term `State' means each of the several 
States of the United States, the District of Columbia, and each 
territory or possession of the United States.'';
(H) in paragraph (19), as so redesignated--
(i) by redesignating subparagraphs (G) and 
(H) as subparagraphs (H) and (I), respectively; 
and
(ii) by inserting after subparagraph (F) 
the following:
``(G) activities to map, track, dismantle, and 
disrupt the financial enablers of drug trafficking 
organizations, transnational criminal organizations, 
and money launderers involved in the manufacture and 
trafficking of drugs in the United States and in 
foreign countries;''; and
(I) by inserting at the end the following:
``(20) United states.--The term `United States', when used 
in a geographical sense, means all of the States, the District 
of Columbia, and the territories and possessions of the United 
States, and any waters within the jurisdiction of the United 
States.
``(21) Evidence.--The term `evidence' has the meaning given 
that term in section 3561 of title 44, United States Code.'';
(2) in section 703(d) (21 U.S.C. 1702(d))--
(A) in paragraph (5)(B), by striking ``accepted by 
a contractor to be used in its performance of a 
contract for the Office.'' and inserting the following: 
``accepted--
``(i) by a contractor (or subcontractor 
thereof at any tier) for use in its performance 
of a contract for the Office; or
``(ii) by a grant recipient (or subgrantee 
thereof at any tier) for use in carrying out an 
award related to a fund administered by the 
Office.''; and
(B) in paragraph (6), by inserting after 
``paragraph (5)'' the following: ``and the registry 
shall be sent to the appropriate Congressional 
committees'';
(3) in section 704 (21 U.S.C. 1703)--
(A) in subsection (a)(1)(C), by striking ``shall'' 
and inserting ``may'';
(B) in subsection (b)--
(i) in paragraph (16), by inserting after 
``to treat addiction'' the following: ``, 
encourage primary substance use prevention, and 
increase accessibility and effectiveness of 
life-saving opioid antagonists or reversal 
agents, such as naloxone'';
(ii) by striking paragraph (20);
(iii) by redesignating paragraph (21) as 
paragraph (20);
(iv) in paragraph (20), as so redesignated, 
by striking the period at the end and inserting 
``; and''; and
(v) by inserting at the end the following:
``(21) shall coordinate with the Secretary of Homeland 
Security, the Attorney General, and the Secretary of State 
regarding the status of the enforcement of clauses (i) and (ii) 
of subparagraph (A) and subparagraph (B) of section 237(a)(2) 
(8 U.S.C. 1227(a)(2)) and subparagraphs (A) and (C) of section 
212(a)(2) (8 U.S.C. 1182(a)(2)) for the purposes of ensuring 
such drug control and illicit drug trafficking enforcement 
activities are adequately resourced.'';
(C) in subsection (c)--
(i) in paragraph (1)(C), by striking 
``supply reduction, and State, local, and 
tribal affairs, including any drug law 
enforcement activities'' and inserting the 
following: ``supply reduction, accessibility to 
life-saving opioid antagonists or reversal 
agents, such as naloxone, and State, local, and 
Tribal affairs, including any drug related law 
enforcement activities'';
(ii) in paragraph (3)(C)--
(I) in clause (ii), by inserting 
after ``United States'' the following: 
``, including at and between the ports 
of entry,'';
(II) in clause (iii), by striking 
``; and'' and inserting a semicolon;
(III) in clause (iv), by striking 
the period at the end and inserting ``; 
and''; and
(IV) by inserting at the end the 
following new clause:
``(v) requests funding for activities that 
facilitate illicit drug use, but not including 
overdose reversal medications, drug checking, 
or testing technology.'';
(D) in subsection (d)(8)(F)(ii), by striking ``and 
at United States ports of entry by officers and 
employees of National Drug Control Program agencies and 
domestic and foreign law enforcement officers'' and 
inserting the following: ``and at and between United 
States ports of entry by officers and employees of 
National Drug Control Program agencies and domestic and 
foreign law enforcement officers'';
(E) in subsection (i)--
(i) in paragraph (1)(A), by striking ``to 
address illicit drug use issues'' and inserting 
the following: ``to address illicit drug use, 
prevention and treatment of overdose and 
addiction, and law enforcement activities''; 
and
(ii) in paragraph (2), by striking ``2023'' 
and inserting ``2031''; and
(F) in subsection (k)--
(i) in the heading, by striking ``Harm 
Reduction Programs'' and inserting ``Substance 
Use Prevention, Harm Reduction, and Life-saving 
Treatment Programs''; and
(ii) in the first sentence, by inserting 
after ``drug addiction and use'' the following: 
``with the primary goal being the prevention of 
initial or continued use and the fostering of 
life-saving opioid antagonists or reversal 
agents, such as naloxone'';
(4) in section 705 (21 U.S.C. 1704)--
(A) in subsection (a)(3)--
(i) in subparagraph (A), by inserting after 
``Federal Government'' the following: ``and 
such lands owned by a foreign principal (as 
such term in defined in section 1(b) of the 
Foreign Agents Registration Act of 1938 (22 
U.S.C. 611))'';
(ii) in subparagraph (B)--
(I) by inserting after ``the 
preceding year'' the following: ``, 
along with historical comparisons over 
the prior 20 years,'';
(II) in clause (i)--
(aa) by inserting after 
``seizing drugs,'' the 
following: ``including 
precursor chemicals,''; and
(bb) by striking ``; and'' 
and inserting a semicolon;
(III) in clause (ii), by striking 
the period at the end and inserting ``; 
and''; and
(IV) by inserting at the end the 
following new clause:
``(iii) the effects of trends of encounters 
of inadmissible aliens at and between the ports 
of entry, and the effect of any increases or 
changes in the level of trade and travel, on 
the capacity and ability of the Department of 
Homeland Security components to interdict and 
prevent the unlawful entry of illicit drugs 
into the United States by any means.''; and
(iii) in subparagraph (D)--
(I) by inserting after ``the 
preceding year'' the following: ``, 
along with historical comparisons over 
the prior 20 years,''; and
(II) in clause (iii), by inserting 
after ``seizing drugs,'' the following: 
``including precursor chemicals,'';
(B) in subsection (e)(2), by inserting before the 
period at the end the following: ``and $3,000,000 for 
each of fiscal years 2025 through 2031''; and
(C) in subsection (f)--
(i) in paragraph (2), by inserting after 
``agency shall'' the following: ``, in 
accordance with guidelines issued by the 
Director for standard definitions, 
identification, and review procedures,''; and
(ii) by striking paragraph (4);
(5) in section 706 (21 U.S.C. 1705)--
(A) in subsection (c)--
(i) in paragraph (1)--
(I) by striking subparagraph (D);
(II) in subparagraph (H)--
(aa) by inserting after 
``identifying existing'' the 
following: ``evidence,''; and
(bb) by striking ``will 
obtain such data'' and 
inserting ``will ensure such 
data is obtained'';
(III) in subparagraph (J)(ii), by 
inserting ``evidence,'' before 
``data'';
(IV) in subparagraph (L), by 
inserting ``evidence'' after ``Such 
other''; and
(V) in subparagraph (M)(iv), by 
inserting ``storing and retrieving,'' 
after ``collecting,'';
(ii) in paragraph (2)--
(I) by redesignating subparagraphs 
(E) and (F) as subparagraphs (G) and 
(H), respectively; and
(II) by inserting after 
subparagraph (D) the following new 
subparagraphs:
``(E) The Administrator of the Office of 
Information and Regulatory Affairs.
``(F) The Chief Data Officers Council.'';
(iii) in paragraph (3)--
(I) in subparagraph (B)(ii)--
(aa) in subclause (I), by 
striking ``; and'' and 
inserting a semicolon;
(bb) in subclause (II), by 
striking the period at the end 
and inserting ``; and''; and
(cc) by inserting at the 
end the following new 
subclause:
``(III) an analysis of the effects 
of trends of encounters of inadmissible 
aliens at and between the ports of 
entry, and the effect of any increases 
or changes in the level of trade and 
travel, on the capacity and ability of 
the Department of Homeland Security to 
interdict and prevent the unlawful 
entry of illicit drugs into the United 
States by any means.''; and
(II) by adding at the end the 
following new subparagraph:
``(D) Requirement for caribbean border 
counternarcotics strategy.--
``(i) Purposes.--The Caribbean Border 
Counternarcotics Strategy shall--
``(I) set forth the strategy of the 
Federal Government for preventing the 
illegal trafficking of drugs through 
the Caribbean region into the United 
States, including through ports of 
entry, between ports of entry, and 
across air and maritime approaches;
``(II) state the specific roles and 
responsibilities of each relevant 
National Drug Control Program agency 
for implementing the strategy;
``(III) identify the specific 
resources required to enable the 
relevant National Drug Control Program 
agencies to implement the strategy, to 
the extent practicable; and
``(IV) be designed to promote, and 
not hinder, legitimate trade and 
travel.
``(ii) Specific content related to puerto 
rico and the united states virgin islands.--The 
Caribbean Border Counternarcotics Strategy 
shall include--
``(I) a strategy to prevent the 
illegal trafficking of drugs to or 
through Puerto Rico and the United 
States Virgin Islands, including 
measures to substantially reduce drug-
related violent crime on such islands; 
and
``(II) recommendations for 
additional assistance or authorities, 
if any, needed by Federal, State, and 
local law enforcement agencies relating 
to the strategy, including an 
evaluation of Federal technical and 
financial assistance, infrastructure 
capacity building, and interoperability 
deficiencies.''; and
(iv) in paragraph (5), by striking ``data'' 
each place it appears and inserting ``evidence, 
data,'';
(B) in subsection (f)--
(i) in paragraph (1), by striking 
``publicly available in a machine-readable 
format'' and inserting the following: 
``publicly available as an open Government data 
asset (as such term is defined in section 3502 
of title 44, United States Code)'';
(ii) in paragraph (2), by inserting after 
``searchable format'' the following: 
``available for bulk download to the extent 
practicable''; and
(iii) by amending paragraph (3) to read as 
follows:
``(3) Data.--The data included in the Drug Control Data 
Dashboard shall be updated annually with final data, and to the 
extent practicable, updated quarterly with provisional data, 
that aligns with the goals of the performance measurement 
system required under subsection (h) and include, at a minimum, 
the following:
``(A) For each substance identified by the Director 
as having a significant impact on illicit drug use in 
the United States, data sufficient to--
``(i) assess supply reduction efforts, 
including, to the extent practicable, the total 
amount of substances seized;
``(ii) assess drug use behaviors;
``(iii) estimate the prevalence of 
substance use disorders;
``(iv) show the number of fatal and non-
fatal overdoses; and
``(v) assess the provision of substance use 
disorder treatment.
``(B) Any quantifiable measures the Director 
determines to be appropriate to detail progress toward 
the achievement of the goals of the National Drug 
Control Strategy, including, to the extent practicable, 
data disaggregated by specific geographic areas or sub-
populations of interest.
``(C) Data sufficient to assess the effectiveness 
of such substance use disorder treatments.
``(D) To the extent practicable, data sufficient to 
show the extent of prescription drug diversion, 
trafficking, and misuse in the calendar year and each 
of the previous 3 calendar years.
``(E) Any quantifiable measures the Director 
determines to be appropriate to detail progress toward 
the achievement of the goals of the National Drug 
Control Strategy, including to the extent practicable, 
data disaggregated by specific geographic areas or sub-
populations of interest.''; and
(C) in subsection (g)(2)--
(i) in subparagraph (D), by striking 
``narcotics'' and inserting ``drugs'';
(ii) in subparagraph (E), by striking 
``drug use'' and inserting ``illicit drug use 
and misuse''; and
(iii) in subparagraph (F), by striking 
``drug use'' and inserting ``illicit drug use 
and misuse'';
(6) in section 707 (21 U.S.C. 1706)--
(A) in subsection (l)(2)(F), by inserting ``and 
authorities enforcing illicit drug trafficking laws'' 
after ``task forces'';
(B) in subsection (m)(2), by inserting ``, 
authorities enforcing illicit drug trafficking laws,'' 
after ``agencies'';
(C) in subsection (p)--
(i) in paragraph (5). by striking ``; and'' 
and inserting a semicolon;
(ii) in paragraph (6), by striking the 
period at the end and inserting ``; and''; and
(iii) by inserting at the end the following 
new paragraph:
``(7) $298,579,000 for each of fiscal years 2025 through 
2031.'';
(D) in subsection (r)(3), by striking 
``addiction'';
(E) in subsection (s)--
(i) in the matter before paragraph (1), by 
striking ``The Director'' and inserting 
``Except as provided in subsection (t)(2), the 
Director'';
(ii) in paragraph (2), by striking ``; 
and'' and inserting a semicolon;
(iii) in paragraph (3), by striking the 
period at the end and inserting ``; and''; and
(iv) by adding at the end the following:
``(4) enhancing fentanyl seizure and interdiction 
activities.''; and
(F) by adding at the end the following:
``(t) Supplemental Grants for Fentanyl Interdiction Activities.--
``(1) Minimum allocation of funds for fentanyl interdiction 
activities.--Of the amounts allocated for grants under 
subsection (s), not less than $5,000,000 shall be allocated for 
the purpose of making grants under subsection (s)(4).
``(2) Additional funds.--In addition to amounts allocated 
under subparagraph (A) for the purpose of making grants under 
subsection (s)(4), the Director may use amounts otherwise 
appropriated to carry out this section for such purpose.
``(u) Additional Judiciary Prosecutorial Resources.--
``(1) Temporary reassignment of assistant united states 
attorneys.--
``(A) Authority.--The Attorney General may identify 
assistant United States attorneys who may be made 
available for temporary reassignment under subsection 
(b)(2) for a period of time determined by the Attorney 
General in coordination with the Director, during which 
an assistant United States attorney shall prioritize 
the investigation and prosecution of organizations and 
individuals trafficking in fentanyl or fentanyl 
analogues.
``(B) Extension of reassignment.--Such reassignment 
may be extended by the Attorney General for such time 
as may be necessary to conclude any ongoing 
investigation or prosecution in which the assistant 
United States attorney is engaged.
``(2) Process for temporary reassignment.--The Attorney 
General may establish a process under which the Director, in 
consultation with the Executive Boards of each designated high 
intensity drug trafficking area, may request such an assistant 
United States attorney to be so temporarily reassigned.
``(v) Use of Funds To Combat Fentanyl Trafficking.--
``(1) Requirement.--As part of the documentation that 
supports the President's annual budget request for the Office, 
the Director shall submit to Congress a report describing the 
use of HIDTA funds for the purposes of enhancing fentanyl 
seizure and interdiction activities under subsection (s)(4) or 
(t) and to investigate and prosecute organizations and 
individuals trafficking in fentanyl or fentanyl analogues in 
the prior calendar year.
``(2) Contents.--The report shall include--
``(A) the amounts of fentanyl or fentanyl analogues 
seized by HIDTA-funded initiative in the area during 
the previous year; and
``(B) law enforcement intelligence and predictive 
data from the Drug Enforcement Administration showing 
patterns and trends in abuse, trafficking, and 
transportation in fentanyl and fentanyl analogues.
``(w) Protection From Unreasonable Search and Seizure.--Any program 
or activity that receives funds made available under this section shall 
be conducted in a manner consistent with the requirements of the Fourth 
Amendment to the Constitution of the United States.
``(x) Report on Data Analytical Services Program.--
``(1) Report.--With respect to the Data Analytical Services 
program (formally known as Hemisphere), and any successor 
program, the Director shall submit to the Committee on 
Oversight and Accountability and the Committee on the Judiciary 
of the House of Representatives, and the Committee on the 
Judiciary of the Senate a report every two years on any 
activities of the program--
``(A) funded by the Office; and
``(B) carried out in two years prior to the 
submission of the report.
``(2) Contents of report.--The report required by paragraph 
(1) shall include the following:
``(A) A documentation of any activities of the Data 
Analytical Services program, including--
``(i) the amount of searches conducted for 
each HIDTA; and
``(ii) each requesting local law 
enforcement jurisdiction.
``(B) Information on how the program was funded and 
how funds were expended under the program, including 
information on any--
``(i) funding sources derived from each 
HIDTA's funding allocation for a HIDTA, or any 
other source of funding, for the program; and
``(ii) payments made by the program to any 
non-governmental entity or external vendor.
``(C) A description of any policies and guidelines 
provided to HIDTA personnel and local law enforcement 
jurisdictions governing the operation of the program in 
order to ensure that such program does not infringe on 
rights protected under the Fourth Amendment or violate 
legally protected privacy of United States citizens or 
individuals legally in the United States, along with 
any recommendations by the Director to strengthen such 
policies and guidelines.'';
(7) in section 709(f)(1) (21 U.S.C. 1708(f)(1))--
(A) by striking ``shall'' and inserting ``may'';
(B) in subparagraph (A), by striking ``abuse'' and 
inserting ``use or misuse''; and
(C) in subparagraph (D)(i), by striking ``addiction 
issues'' and inserting ``substance use disorders'';
(8) in section 709 (21 U.S.C. 1708)--
(A) in subsection (f)(2)(B)(iii), by inserting 
after ``professionals'' the following: ``including 
experts in evidence-based media campaigns, education, 
and evaluation''; and
(B) in subsection (g), by striking ``2023'' and 
inserting ``2031'';
(9) in section 711 (21 U.S.C. 1710), including the 
headings, by striking ``Command and Control Plan'' each place 
it appears and inserting ``Strategic Plan''; and
(10) in section 714 (21 U.S.C. 1711), by inserting before 
the period at the end the following: ``and $20,000,000 for each 
of fiscal years 2025 through 2031''.
(b) Amendments to the Anti-Drug Abuse Act of 1988.--The Anti-Drug 
Abuse Act of 1988 (Public Law 100-690) is amended--
(1) in section 1024 (21 U.S.C. 1524)--
(A) in subsection (a), by inserting before the 
period at the end the following: ``and $109,000,000 for 
each of fiscal years 2025 through 2031''; and
(B) in subsection (b), by striking ``8 percent'' 
and inserting ``10 percent''; and
(2) in section 1032(b) (21 U.S.C. 1532(b))--
(A) by striking ``$125,000'' each place the term 
appears and inserting ``$150,000''; and
(B) in paragraph (3)--
(i) by striking subparagraph (A) and 
inserting the following:
``(A) In general.--Subject to subparagraph (F), the 
Administrator may award up to 2 additional grants under 
this paragraph to an eligible coalition awarded a grant 
under paragraph (1) or (2) for any first fiscal year 
after the end of the 4-year or 9-year period following 
the period of the initial or subsequent grant under 
paragraph (1) or (2), as the case may be.'';
(ii) in subparagraph (B), by striking ``a 
renewal grant'' and inserting ``up to 2 renewal 
grants'';
(iii) in subparagraph (C), by striking ``an 
additional grant'' and inserting ``the 
additional grants''; and
(iv) by striking subparagraph (D) and 
inserting the following:
``(D) Renewal grants.--Subject to subparagraph (F), 
the Administrator may award a renewal grant to a grant 
recipient under this paragraph for each fiscal year of 
the 4-fiscal-year period following the first fiscal 
year for which an additional grant under this paragraph 
is awarded in an amount not to exceed the amount of 
non-Federal funds raised by the coalition, including 
in-kind contributions, for that fiscal year.''.
(c) Reauthorization of the National Community Anti-Drug Coalition 
Institute.--Section 4(d) of Public Law 107-82 (21 U.S.C. 1521 note) is 
amended by striking paragraph (2) and inserting the following:
``(2) Disbursement.--The Director shall, using amounts 
authorized to be appropriated by section 1024 of the Anti-Drug 
Abuse Act of 1988 (21 U.S.C. 1524), disburse $2,500,000 made 
available under subsection (a), for each of the fiscal years 
2025 through 2031.''.
(d) Reauthorization of Community-based Coalition Enhancement Grants 
to Address Local Drug Crises.--Section 103 of the Comprehensive 
Addiction and Recovery Act of 2016 (21 U.S.C. 1536) is amended--
(1) in subsection (a)--
(A) in paragraph (1)--
(i) in the heading, by striking 
``Administrator'' and inserting ``assistant 
secretary''; and
(ii) by striking ``Administrator'' each 
place it appears and inserting ``Assistant 
Secretary'';
(B) in paragraph (4)(B), by striking ``abuse'' and 
inserting ``use or misuse''; and
(C) in paragraph (5)(A), by striking ``abuse'' and 
inserting ``use or misuse'';
(2) in subsection (b), by striking ``Administrator'' and 
inserting ``Assistant Secretary'';
(3) in subsection (h), by striking ``Administrator'' and 
inserting ``Assistant Secretary''; and
(4) in subsection (i), by inserting before the period at 
the end the following: ``and $5,200,000 for each of fiscal 
years 2025 through 2031''.
(e) Report Regarding Life-saving Opioid Antagonists or Reversal 
Agents.--
(1) Amendment.--The Office of National Drug Control Policy 
Reauthorization Act of 2006 (Public Law 109-469) is amended by 
adding at the end the following new section:

``SEC. 1121. REQUIREMENT FOR LIFE SAVING OPIOID OVERDOSE REVERSAL 
STUDY.

``(a) Finding.--Congress finds that it is vital to support access 
to treatment and emergency intervention tools to address drug addiction 
while also pursuing strategies to ensure communities have readily 
available access to life-saving drug overdose reversal medications, 
including opioid antagonists or reversal agents, such as naloxone, in 
case of an emergency.
``(b) Report.--Not later than 180 days after the date of the 
enactment of this section, the Director of the Office of National Drug 
Control Policy shall submit to Congress a report that contains the 
following:
``(1) A summary of the relevant roles, responsibilities, 
and authorities of each relevant National Drug Control Program 
agency to ensure that life-saving drug overdose reversal 
medications are readily available in case of an emergency, 
including life-saving opioid antagonists or reversal agents, 
such as naloxone, across the Nation.
``(2) A strategy for the Federal Government to ensure that 
State, local, and Tribal governments, and agencies thereof 
including law enforcement and public health and safety 
entities, have life-saving drug overdose reversal medications 
readily available in case of an emergency, including life-
saving opioid antagonists or reversal agents, such as naloxone, 
which at a minimum identifies--
``(A) any Federal and State policies and actions 
necessary for the relevant National Drug Control 
Program agencies to take to address--
``(i) the challenges faced by pharmacists, 
prescription drug providers, dispensers 
(including manufacturers, distributors, and 
retailers), and other health care providers, to 
make such medications readily available to 
patients over the counter for emergency use;
``(ii) the challenges faced by pharmacists, 
health care providers, and State health 
officials to educate the public on the risks 
and benefits of such medications, including how 
to effectively use such medications; and
``(iii) the appropriate training of State 
and local health care providers and first 
responders on the use of such medications; and
``(B) identifies any budgetary resources, personnel 
resources, licensing requirements, and legal 
authorities that relevant National Drug Control Program 
agencies needs to enable the availability of such life-
saving emergency drug overdose medications;
``(3) A summary of policies in effect before the submission 
of the report that are administered by--
``(A) the Director of the Office National Drug 
Control Policy;
``(B) the Secretary of Health and Human Services; 
and
``(C) each National Drug Control Program agency, as 
applicable.
``(4) A summary of the specific actions taken over the 
previous 10 years before the submission of the report by the 
Substance Abuse and Mental Health Services Administration and 
the Drug Enforcement Administration to coordinate with one 
another and with State health agencies to ensure that--
``(A) such treatments, including medications, are 
accessible to the public; and
``(B) appropriate public education on the use of, 
and the risks and benefits of, such treatments, 
including medications, are readily available.
``(c) Updates.--Any significant update made to the strategy 
included in the report required by paragraph (2)(B) after such report 
is submitted shall be included in the next National Drug Control 
Strategy submitted to Congress after such update is made.''.
(2) Technical and conforming amendment.--The Table of 
Contents for the Office of National Drug Control Policy 
Reauthorization Act of 2006 is amended by adding at the end the 
following new item:

``Sec. 1121. Requirement for Life Saving Opioid Overdose 
Reversal Study.''.
(f) Report on Pill Press Machines.--Not later than 120 days after 
the date of the enactment of this Act, the Director of the Office of 
Drug Control Policy shall make public a report that includes an 
analysis of and a description of strategic ways to regulate the 
shipment of pill press machines and their critical parts using reports 
previously prepared by the Office.

Passed the House of Representatives December 5, 2024.

Attest:

KEVIN F. MCCUMBER,

Clerk.